Listed

Cadrenal Therapeutics, Inc.

CVKDNasdaqCIK 1937993HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.3m, Q2 FY2026
Net income−$3.3m, Q2 FY2026
Cadrenal Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cost of revenue$k0.0Cost of revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2023-11-09, accession 0001213900-23-084937. Derived: 9-month figure less the 6-month figure.Report this figure0.0Cost of revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-K filed 2024-03-11, accession 0001213900-24-021133. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k244Research and development, Q3 FY2023, three months to 2023-09-30$243.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure361Research and development, Q4 FY2023, three months to 2023-12-31$361.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figure629Research and development, Q1 FY2024, three months to 2024-03-31$629.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure1,254Research and development, Q2 FY2024, three months to 2024-06-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure785Research and development, Q3 FY2024, three months to 2024-09-30$784.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure1,538Research and development, Q4 FY2024, three months to 2024-12-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure1,668Research and development, Q1 FY2025, three months to 2025-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure1,077Research and development, Q2 FY2025, three months to 2025-06-30$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure688Research and development, Q3 FY2025, three months to 2025-09-30$688.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure666Research and development, Q4 FY2025, three months to 2025-12-31$666.3k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure772Research and development, Q1 FY2026, three months to 2026-03-31$771.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure705Research and development, Q2 FY2026, three months to 2026-06-30$705.2k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Operating income$k(1,143)Operating income, Q3 FY2023, three months to 2023-09-30−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure(1,264)Operating income, Q4 FY2023, three months to 2023-12-31−$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figure(1,756)Operating income, Q1 FY2024, three months to 2024-03-31−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure(2,467)Operating income, Q2 FY2024, three months to 2024-06-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure(2,460)Operating income, Q3 FY2024, three months to 2024-09-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure(4,278)Operating income, Q4 FY2024, three months to 2024-12-31−$4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(3,928)Operating income, Q1 FY2025, three months to 2025-03-31−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(3,734)Operating income, Q2 FY2025, three months to 2025-06-30−$3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure(2,734)Operating income, Q3 FY2025, three months to 2025-09-30−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure(3,065)Operating income, Q4 FY2025, three months to 2025-12-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(2,514)Operating income, Q1 FY2026, three months to 2026-03-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(3,340)Operating income, Q2 FY2026, three months to 2026-06-30−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Interest expense$k0.0Interest expense, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-09, accession 0001213900-23-084937. Derived: 9-month figure less the 6-month figure.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(1,036)Net income, Q3 FY2023, three months to 2023-09-30−$1.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure(1,144)Net income, Q4 FY2023, three months to 2023-12-31−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figure(1,663)Net income, Q1 FY2024, three months to 2024-03-31−$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure(2,393)Net income, Q2 FY2024, three months to 2024-06-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure(2,408)Net income, Q3 FY2024, three months to 2024-09-30−$2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure(4,187)Net income, Q4 FY2024, three months to 2024-12-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(3,845)Net income, Q1 FY2025, three months to 2025-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(3,667)Net income, Q2 FY2025, three months to 2025-06-30−$3.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure(2,686)Net income, Q3 FY2025, three months to 2025-09-30−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure(3,039)Net income, Q4 FY2025, three months to 2025-12-31−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(2,497)Net income, Q1 FY2026, three months to 2026-03-31−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(3,323)Net income, Q2 FY2026, three months to 2026-06-30−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Diluted EPS$ per share(1.01)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figurenot reported(1.56)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure(2.24)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$2.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure(2.18)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figurenot reported(2.09)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(1.87)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure(1.31)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figurenot reported(1.04)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(1.14)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Basic EPS$ per share(1.01)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figurenot reported(1.56)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure(2.24)Basic EPS, Q2 FY2024, three months to 2024-06-30−$2.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure(2.18)Basic EPS, Q3 FY2024, three months to 2024-09-30−$2.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figurenot reported(2.09)Basic EPS, Q1 FY2025, three months to 2025-03-31−$2.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(1.87)Basic EPS, Q2 FY2025, three months to 2025-06-30−$1.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure(1.31)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figurenot reported(1.04)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(1.14)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure

Balance sheet

Cash and equivalents$2.4m, Q2 FY2026
Shareholders' equity$4.1m, Q2 FY2026
Cadrenal Therapeutics, Inc., balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30period not labelled2025-08-06Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m8.4Cash and equivalents, FY2023, at 2023-12-31$8.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure6.6Cash and equivalents, Q1 FY2024, at 2024-03-31$6.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure5.0Cash and equivalents, Q2 FY2024, at 2024-06-30$5.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure4.4Cash and equivalents, Q3 FY2024, at 2024-09-30$4.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure10.0Cash and equivalents, FY2024, at 2024-12-31$10.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure7.3Cash and equivalents, Q1 FY2025, at 2025-03-31$7.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure5.6Cash and equivalents, Q2 FY2025, at 2025-06-30$5.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure5.0Cash and equivalents, period not labelled, at 2025-08-06$5.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure3.9Cash and equivalents, Q3 FY2025, at 2025-09-30$3.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure4.0Cash and equivalents, FY2025, at 2025-12-31$4.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure2.3Cash and equivalents, Q1 FY2026, at 2026-03-31$2.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure2.4Cash and equivalents, Q2 FY2026, at 2026-06-30$2.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Current assets$m8.5Current assets, FY2023, at 2023-12-31$8.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001213900-25-023759.Report this figure7.0Current assets, Q1 FY2024, at 2024-03-31$7.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure5.4Current assets, Q2 FY2024, at 2024-06-30$5.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure4.7Current assets, Q3 FY2024, at 2024-09-30$4.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure10.1Current assets, FY2024, at 2024-12-31$10.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure7.9Current assets, Q1 FY2025, at 2025-03-31$7.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure6.0Current assets, Q2 FY2025, at 2025-06-30$6.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figurenot reported4.1Current assets, Q3 FY2025, at 2025-09-30$4.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure4.3Current assets, FY2025, at 2025-12-31$4.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure2.9Current assets, Q1 FY2026, at 2026-03-31$2.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure5.6Current assets, Q2 FY2026, at 2026-06-30$5.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Total assets$m8.5Total assets, FY2023, at 2023-12-31$8.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001213900-25-023759.Report this figure7.0Total assets, Q1 FY2024, at 2024-03-31$7.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure5.5Total assets, Q2 FY2024, at 2024-06-30$5.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure4.7Total assets, Q3 FY2024, at 2024-09-30$4.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure10.1Total assets, FY2024, at 2024-12-31$10.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure8.0Total assets, Q1 FY2025, at 2025-03-31$8.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure6.0Total assets, Q2 FY2025, at 2025-06-30$6.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figurenot reported4.1Total assets, Q3 FY2025, at 2025-09-30$4.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure4.3Total assets, FY2025, at 2025-12-31$4.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure2.9Total assets, Q1 FY2026, at 2026-03-31$2.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure5.6Total assets, Q2 FY2026, at 2026-06-30$5.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Current liabilities$m0.8Current liabilities, FY2023, at 2023-12-31$826.9k. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001213900-25-023759.Report this figure0.9Current liabilities, Q1 FY2024, at 2024-03-31$856.3k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure1.5Current liabilities, Q2 FY2024, at 2024-06-30$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure1.3Current liabilities, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure2.7Current liabilities, FY2024, at 2024-12-31$2.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure1.8Current liabilities, Q1 FY2025, at 2025-03-31$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure1.7Current liabilities, Q2 FY2025, at 2025-06-30$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figurenot reported1.4Current liabilities, Q3 FY2025, at 2025-09-30$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure1.6Current liabilities, FY2025, at 2025-12-31$1.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure1.1Current liabilities, Q1 FY2026, at 2026-03-31$1.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure1.5Current liabilities, Q2 FY2026, at 2026-06-30$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Total liabilities$m0.8Total liabilities, FY2023, at 2023-12-31$826.9k. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001213900-25-023759.Report this figure0.9Total liabilities, Q1 FY2024, at 2024-03-31$856.3k. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure1.5Total liabilities, Q2 FY2024, at 2024-06-30$1.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure1.3Total liabilities, Q3 FY2024, at 2024-09-30$1.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure2.7Total liabilities, FY2024, at 2024-12-31$2.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure1.8Total liabilities, Q1 FY2025, at 2025-03-31$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure1.7Total liabilities, Q2 FY2025, at 2025-06-30$1.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figurenot reported1.4Total liabilities, Q3 FY2025, at 2025-09-30$1.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure1.6Total liabilities, FY2025, at 2025-12-31$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure1.1Total liabilities, Q1 FY2026, at 2026-03-31$1.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure1.5Total liabilities, Q2 FY2026, at 2026-06-30$1.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m7.7Shareholders' equity, FY2023, at 2023-12-31$7.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001213900-26-036946.Report this figure6.2Shareholders' equity, Q1 FY2024, at 2024-03-31$6.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure4.0Shareholders' equity, Q2 FY2024, at 2024-06-30$4.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure3.4Shareholders' equity, Q3 FY2024, at 2024-09-30$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure7.4Shareholders' equity, FY2024, at 2024-12-31$7.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure6.1Shareholders' equity, Q1 FY2025, at 2025-03-31$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure4.3Shareholders' equity, Q2 FY2025, at 2025-06-30$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figurenot reported2.7Shareholders' equity, Q3 FY2025, at 2025-09-30$2.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure2.7Shareholders' equity, FY2025, at 2025-12-31$2.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure1.8Shareholders' equity, Q1 FY2026, at 2026-03-31$1.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure4.1Shareholders' equity, Q2 FY2026, at 2026-06-30$4.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure

Cash flow

Operating cash flow−$2.2m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Cadrenal Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(628)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$627.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001213900-24-095393. Derived: 9-month figure less the 6-month figure.Report this figure(694)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$694.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figure(1,836)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure(1,529)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001213900-25-073885. Derived: 6-month figure less the 3-month figure.Report this figure(2,201)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001213900-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure(1,791)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(4,649)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(3,026)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001213900-26-089153. Derived: 6-month figure less the 3-month figure.Report this figure(2,357)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001213900-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure(2,570)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figure(3,002)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure(2,233)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001213900-26-089153. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$1. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001213900-24-095393. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001213900-25-023759. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported3.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$3.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001213900-26-089153. Derived: 6-month figure less the 3-month figure.Report this figure1.9Capital expenditure, Q3 FY2025, three months to 2025-09-30$1.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001213900-25-107816. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-31, accession 0001213900-26-036946. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)2.91m, Q2 FY2026
Cadrenal Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares8.0Diluted shares (weighted), period not labelled, three months to 2022-09-308,037,218 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001213900-23-084937.Report this figure10.8Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3110,772,493 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001213900-24-041014.Report this figure11.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3011,722,754 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001213900-24-066107.Report this figure1.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-301,026,415 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001213900-24-095393.Report this figure1.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-311,067,231 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001213900-25-040788.Report this figure1.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-301,067,231 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001213900-25-073885.Report this figure1.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-301,104,005 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure1.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-311,844,072 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure2.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-301,961,642 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure2.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-302,044,033 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001213900-25-107816.Report this figure2.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-312,407,665 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001213900-26-053074.Report this figure2.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-302,913,225 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure

Shares outstanding: 3.57mShares outstanding, period not labelled, at 2026-08-133,567,592 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001213900-26-089153.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.